MTAR Tech Q3 Review - Challenges In Fuel Cell Business Inherent Part Of An Evolving Technology: Yes Securities

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy..Yes Securities Report.MTAR Technologies Ltd.’s Q3 FY24 print came in a significant quantum below expectations as the phasein/out of the earlier YUMA hotbox to Santacruz has led to an interim dent on the financial performance. With revenue falling 26%, the impact on Ebitda and profit after tax was much higher. While clean energy segment revenue almost halved YoY, Products segment (average selling price assemblies, Roller Screws etc.) jumped more than four times.The company delivered even fewer hotboxes (500 units) than Q2 FY24 which saw only the delivery of Santacruz hotboxes while YUMA and Keeylocko saw no deliveries..While the quarter might come as a shock in comparison to the past many quarters of above 30% revenue growth run-rate, the odds of the company returning to similar growth path in FY25 and beyond remain strong. The sudden urgency of a higher efficiency fuel cell could be a move by Bloom to compensate for the perceived increase in green hydrogen project costs in U.S. after the recent guidance of the US Treasury on 45V tax credit. On the flip side, MTAR has been able to make serious in-roads in its aerospace and products business, both of which are expected to garner over 30% of the revenue mix in FY25 (from 13% in FY23). In addition, nuclear revenue is expected to pick up pace starting FY26 with a long runway beyond. The revenue share from Bloom is expected to come down to ~42% in FY26 from 74% in FY23 which would help in reducing revenue concentration and improved margin coming in from increased products business. We have reduced our FY25E/FY26E EPS estimates by 9%/16% respectively factoring a significantly lower than expected EPS in FY24. Maintain 'Buy' with a reduced target price of Rs 2,350 (32 times FY26 EPS)..Click on the attachment to read the full report:.Supriya Lifescience Q3 Review - Strong Growth Across Board On Favorable Geographical, Product Mix: DRChoksey.DISCLAIMERThis report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit..Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

MTAR Tech Q3 Review - Challenges In Fuel Cell Business Inherent Part Of An Evolving Technology: Yes Securities

While the quarter might come as a shock in comparison to the past many quarters of above 30% revenue growth run-rate, the odds of MTAR returning to similar growth path in FY25 and beyond remain strong

NDTV Profit

NDTV Profit

Follow Us

DOWNLOAD THE APP

MTAR Tech Q3 Review - Challenges In Fuel Cell Business Inherent Part Of An Evolving Technology: Yes Securities

While the quarter might come as a shock in comparison to the past many quarters of above 30% revenue growth run-rate, the odds of MTAR returning to similar growth path in FY25 and beyond remain strong

Choose a plan

Follow Us

DOWNLOAD THE APP